Consensus BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Real-time Estimate Cboe BZX Other stock markets 12:05:27 2024-04-24 pm EDT			5-day change	1st Jan Change
24.94 ^USD	-2.06%		-0.08%	-38.17%

Apr. 07	BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	CI
Mar. 20	JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	MT

Evolution of the average Target Price on BridgeBio Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8f38507ae.SHFXFpGXUlpvCqiQBeoOTMWq-MEi4qiZV0QTp3xa1Is.HS4xX9-jIzM9UtHZQZ1sNpXJnqZ1q5CtPQwh0Tkj5fx5RHpy9-UePlxgxw~4538311ebbb2af40b2942cc871846faa

Analyst Recommendations on BridgeBio Pharma, Inc.

JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	Mar. 20	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating	Mar. 19	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Overweight Rating	Mar. 11	MT
Mizuho Securities Trims Price Target on BridgeBio Pharma to $53 From $60, Keeps Buy Rating	Mar. 04	MT
Citigroup Adjusts BridgeBio Pharma Price Target to $46 From $42, Maintains Buy Rating	Feb. 23	MT
Citigroup Adjusts Price Target on BridgeBio Pharma to $46 From $42, Keeps Buy Rating	Feb. 23	MT
HC Wainwright Raises BridgeBio Pharma Price Target to $47 From $22, Maintains Buy Rating	Jan. 29	MT
JPMorgan Adjusts BridgeBio Pharma Price Target to $35 From $38, Maintains Overweight Rating	Nov. 24	MT
Citigroup Starts BridgeBio Pharma With Buy Rating, $42 Price Target	Nov. 07	MT
BridgeBio Pharma Says Heart Disease Drug Showed 81% Survival Rate in Phase 3 Study	23-08-28	MT
JPMorgan Adjusts Price Target on BridgeBio Pharma to $38 From $42, Maintains Overweight Rating	23-08-17	MT
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Buy Rating	23-08-14	MT
Raymond James Raises Price Target on BridgeBio Pharma to $46 From $29, Maintains Outperform Rating	23-07-18	MT
Goldman Sachs Adjusts Price Target on BridgeBio Pharma to $50 From $29, Maintains Buy Rating	23-07-18	MT
Jefferies Downgrades BridgeBio Pharma to Hold From Buy, Adjusts Price Target to $33 From $24	23-07-18	MT
Mizuho Hikes Price Target on BridgeBio Pharma to $50 From $29, Maintains Buy Rating	23-07-18	MT
In wait-and-see mode before Tesla and Netflix	23-07-17
Mizuho Securities Adjusts BridgeBio Pharma Price Target to $29 From $23, Maintains Buy Rating	23-05-08	MT
Evercore ISI Starts BridgeBio Pharma at Outperform With $40 Price Target	23-04-19	MT
SVB Securities Raises Price Target on BridgeBio Pharma to $27 From $25, Keeps Outperform Rating	23-04-13	MT
Jefferies Adjusts Price Target on BridgeBio Pharma to $24 From $21, Maintains Buy Rating	23-03-07	MT
Goldman Sachs Adjusts Price Target on BridgeBio Pharma to $28 From $20, Maintains Buy Rating	23-03-07	MT
JPMorgan Adjusts Price Target on BridgeBio Pharma to $23 From $18, Maintains Overweight Rating	23-03-07	MT
Raymond James Raises Price Target on BridgeBio Pharma to $29 From $17, Maintains Outperform Rating	23-03-07	MT
SVB Securities Adjusts BridgeBio Pharma Price Target to $26 From $20, Maintains Outperform Rating	23-03-06	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.46 USD

Average target price

50.75 USD

Spread / Average Target

+99.33%

High Price Target

70 USD

Spread / Highest target

+174.94%

Low Price Target

37 USD

Spread / Lowest Target

+45.33%

Consensus detail

Consensus revision (last 18 months)

Analysts covering BridgeBio Pharma, Inc.

JPMorgan Chase
Cantor Fitzgerald
Mizuho Securities
Citigroup
HC Wainwright
Raymond James
Goldman Sachs
Jefferies & Co.
Evercore ISI
SVB Securities LLC
Cowen
SVB Financial
SVB Leerink
UBS
BTIG
BofA Securities
J.P. Morgan Chase

Ratings for BridgeBio Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar